Use of biomarkers to guide decisions on adjuvant systemic therapy forwomenwith early-stage invasive breast cancer: American Society of clinical Oncology clinical practice guideline

Journal of Clinical Oncology

Volumn 34, Issue 10, 2016, Pages 1134-1150

  Harris, Lyndsay N ^a   Ismaila, Nofisat ^b   McShane, Lisa M ^c   Andre, Fabrice ^d   Collyar, Deborah E ^e   Gonzalez Angulo, Ana M ^g   Hammond, Elizabeth H ^f   Kuderer, Nicole M ⁱ   Liu, Minetta C ^j   Mennel, Robert G ^a   Van Poznak, Catherine ^k   Bast, Robert C ^g,h   Hayes, Daniel F ^k  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Patient Advocates in Research   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^j Mayo Clinic   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB; TUMOR MARKER; UROKINASE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; COMORBIDITY; DISEASE FREE SURVIVAL; EVIDENCE BASED PRACTICE; FEMALE; HEALTH DISPARITY; HUMAN; IMMUNOHISTOCHEMISTRY; LABELING INDEX; META ANALYSIS; OVERALL SURVIVAL; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TUMOR ASSOCIATED LEUKOCYTE; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMISTRY; CLINICAL DECISION MAKING; EVIDENCE BASED MEDICINE; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CLINICAL DECISION-MAKING; COMORBIDITY; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84963558666     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.2289     Document Type: Article

References (83)

1. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
2. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43, 2007
3. Wolff AC, Hammond ME, Hicks DG, et al: American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
4. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134:907-922, 2010
5. 4a. Van Poznak C, Somerfield MR, Bast RC, et al: The use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, doi: 10.1200/JCO.2015.61.1459
6. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996
7. Ginsburg GS, Kuderer NM: Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: A common bond. J Clin Oncol 30:4233-4242, 2012
8. Hayes DF, Allen J, Compton C, et al: Breaking a vicious cycle. Sci Transl Med 5:196cm6, 2013
9. McShane LM, Hayes DF: Publication of tumor marker research results: The necessity for complete and transparent reporting. J Clin Oncol 30:4223-4232, 2012
10. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
11. Janes H, Pepe MS, Bossuyt PM, et al: Measuring the performance of markers for guiding treatment decisions. Ann Intern Med 154:253-259, 2011
12. Kaufmann M, Pusztai L; Biedenkopf Expert Panel Members: Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer 117:1575-1582, 2011
13. Polley MY, Freidlin B, Korn EL, et al: Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst 105:1677-1683, 2013
14. Teutsch SM, Bradley LA, Palomaki GE, et al: EGAPP Working Group: The evaluation of genomic applications in practice and prevention (EGAPP) initiative: Methods of the EGAPP Working Group. Genet Med 11:3-14, 2009
15. Botkin JR, Teutsch SM, Kaye CI, et al: EGAPP Working Group: Outcomes of interest in evidencebased evaluations of genetic tests. Genet Med 12:228-235, 2010
16. Micheel CM, Nass SJ, Omenn GS (eds): Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC, National Academies Press, 2012
17. Wolff AC, Hammond ME, Hicks DG, et al: American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138:241-256, 2014
18. Peto R, Davies C, Godwin J, et al: Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet 379:432-444, 2012
19. Sargent DJ, Conley BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027, 2005
20. Freidlin B, McShane LM, Korn EL: Randomized clinical trials with biomarkers: Design issues. J Natl Cancer Inst 102:152-160, 2010
21. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
22. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
23. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010
24. Albain KS, Barlow WE, Shak S, et al: Breast Cancer Intergroup of North America: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
25. Filipits M, Rudas M, Jakesz R, et al: EP Investigators: A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17:6012-6020, 2011
26. Dubsky P, Filipits M, Jakesz R, et al: Austrian Breast and Colorectal Cancer Study Group (ABCSG): EndoPredict improves the prognostic classification derived from common clinical guidelines in ERpositive, HER2-negative early breast cancer. Ann Oncol 24:640-647, 2013
27. Martin M, Brase JC, Calvo L, et al: Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER1/HER2-breast cancer patients: Results from the GEICAM 9906 trial. Breast Cancer Res 16:R38, 2014
28. Dubsky P, Brase JC, Jakesz R, et al: Austrian Breast and Colorectal Cancer Study Group (ABCSG): The EndoPredict score provides prognostic information on late distant metastases in ER1/HER2-breast cancer patients. Br J Cancer 109:2959-2964, 2013
29. Buyse M, Loi S, van't Veer L, et al: TRANSBIG Consortium: Validation and clinical utility of a 70-gene prognostic signature forwomenwith nodenegative breast cancer. J Natl Cancer Inst 98:1183-1192, 2006
30. Mook S, Schmidt MK, Viale G, et al: TRANSBIG Consortium: The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116:295-302, 2009
31. Bueno-de-Mesquita JM, Linn SC, Keijzer R, et al: Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 117:483-495, 2009
32. Knauer M, Cardoso F, Wesseling J, et al: Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 103:1788-1793, 2010
33. Knauer M, Mook S, Rutgers EJ, et al: The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 120:655-661, 2010
34. Drukker CA, van Tinteren H, Schmidt MK, et al: Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat 143:587-592, 2014
35. Filipits M, Nielsen TO, Rudas M, et al: Austrian Breast and Colorectal Cancer Study Group: The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 20:1298-1305, 2014
36. Gnant M, Filipits M, Greil R, et al: Austrian Breast and Colorectal Cancer Study Group: Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25:339-345, 2014
37. Dowsett M, Sestak I, Lopez-Knowles E, et al: Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783-2790, 2013
38. Sgroi DC, Sestak I, Cuzick J, et al: Prediction of late distant recurrence in patients with oestrogenreceptorpositive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the Trans-ATAC study population. Lancet Oncol 14:1067-1076, 2013
39. Jerevall PL, Ma XJ, Li H, et al: Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104:1762-1769, 2011
40. Zhang Y, Schnabel CA, Schroeder BE, et al: Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early-and late-distant recurrence. Clin Cancer Res 19:4196-4205, 2013
41. Ross DT, Kim CY, Tang G, et al: Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin Cancer Res 14:6602-6609, 2008
42. Cuzick J, Dowsett M, Pineda S, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29:4273-4278, 2011
43. Harbeck N, Schmitt M, Meisner C, et al: Chemo-N 0 Study Group: Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO) - recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 49:1825-1835, 2013
44. Rack B, Schindlbeck C, Jückstock J, et al: SUCCESS Study Group: Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 106: dju066, 2014
45. Lucci A, Hall CS, Lodhi AK, et al: Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol 13:688-695, 2012
46. Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 25:1544-1550, 2014
47. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860-867, 2013
48. Province MA, Goetz MP, Brauch H, et al: International Tamoxifen Pharmacogenomics Consortium: CYP2D6 genotype and adjuvant tamoxifen: Meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-227, 2014
49. Goetz MP, Suman VJ, Hoskin TL, et al: CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 19:500-507, 2013
50. Regan MM, Leyland-Jones B, Bouzyk M, et al: Breast International Group (BIG) 1-98 Collaborative Group: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J Natl Cancer Inst 104:441-451, 2012
51. Rae JM, Drury S, Hayes DF, et al: ATAC Trialists: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452-460, 2012
52. Stendahl M, Nilsson S, Wigerup C, et al: p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients. Int J Cancer 127:2851-2858, 2010
53. Viale G, Giobbie-Hurder A, Regan MM, et al: Breast International Group Trial 1-98: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrineresponsive breast cancer: Results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569-5575, 2008
54. Viale G, Regan MM, Dell'Orto P, et al: BIG 1-98 Collaborative and International Breast Cancer Study Groups: Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 22:2201-2207, 2011
55. Pentheroudakis G, Kalogeras KT, Wirtz RM, et al: Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat 116:131-143, 2009
56. Pusztai L, Jeong JH, Gong Y, et al: Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol 27:4287-4292, 2009
57. Tzaida O, Gogas H, Dafni U, et al: Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Oncology 72:388-396, 2007
58. Di Leo A, Desmedt C, Bartlett JMS, et al: HER2/TOP2A Meta-analysis Study Group: HER2 and TOP2A as predictive markers for anthracyclinecontaining chemotherapy regimens as adjuvant treatment of breast cancer: A meta-analysis of individual patient data. Lancet Oncol 12:1134-1142, 2011
59. Tanner M, Isola J, Wiklund T, et al: Scandinavian Breast Group Trial 9401: Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24:2428-2436, 2006
60. Du Y, Zhou Q, Yin W, et al: The role of topoisomerase IIa in predicting sensitivity to anthracyclines in breast cancer patients: A meta-analysis of published literatures. Breast Cancer Res Treat 129:839-848, 2011
61. Hannemann J, Kristel P, van Tinteren H, et al: Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: Predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 95:1334-1341, 2006
62. Nielsen KV, Ejlertsen B, Møller S, et al: The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 47:725-734, 2008
63. O'Malley FP, Chia S, Tu D, et al: Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128:401-409, 2011
64. Pritchard KI, Munro A, O'Malley FP, et al: Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: Evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 trial. Breast Cancer Res Treat 131:541-551, 2012
65. Ladoire S, Mignot G, Dalban C, et al: FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCERPACS 01 trial. Ann Oncol 23:2552-2561, 2012
66. Conforti R, Boulet T, Tomasic G, et al: Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: A biomarker study from two randomized trials. Ann Oncol 18:1477-1483, 2007
67. Hertel PB, Tu D, Ejlertsen B, et al: TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. Breast Cancer Res Treat 132:225-234, 2012
68. Lara JF, Thor AD, Dressler LG, et al: Cancer and Leukemia Group B: p53 expression in nodepositive breast cancer patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res 17:5170-5178, 2011
69. Perez EA, Dueck AC, McCullough AE, et al: Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol 31:2115-2122, 2013
70. Moreno-Aspitia A, Hillman DW, Dyar SH, et al: Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group Adjuvant Trial N9831. Cancer 119:2675-2682, 2013
71. Hayes DF: Targeting adjuvant chemotherapy: A good idea that needs to be proven! J Clin Oncol 30:1264-1267, 2012
72. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
73. Goldhirsch A, Winer EP, Coates AS, et al: Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206-2223, 2013
74. Yerushalmi R, Woods R, Ravdin PM, et al: Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol 11:174-183, 2010
75. Dowsett M, Nielsen TO, A'Hern R, et al: International Ki-67 in Breast Cancer Working Group: Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103:1656-1664, 2011
76. Polley MYC, Leung SCY, McShane LM, et al: International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group: An international Ki67 reproducibility study. J Natl Cancer Inst 105:1897-1906, 2013
77. Sestak I, Cuzick J, Dowsett M, et al: Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol 33:916-922, 2015
78. Howlader N, Noone AM, Krapcho M, et al: Cancer Facts & Figures for African Americans 2013-2014. Atlanta, GA American Cancer Society, 2013
79. American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity: Patientcentered care for older adults with multiple chronic conditions: A stepwise approach from the American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc 60:1957-1968, 2012
80. US Cancer Statistics Working Group: United States Cancer Statistics: 1999-2011 Incidence and mortality web-based report. Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. http://www.cdc.gov/uscs
81. Mead H, Cartwright-Smith L, Jones K, et al: Racial and ethnic disparities in U. S. health care: A chartbook, 2008. http://www.commonwealthfund.org/publications/chartbooks/2008/mar/racial-and-ethnicdisparitiesin-u-s-health-care-a-chartbook
82. Singh M, Ding Y, Zhang LY, et al: Distinct breast cancer subtypes in women with early-onset disease across races. Am J Cancer Res 4:337-352, 2014
83. Stark A, Kucera G, Lu M, et al: Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients. Int J Qual Health Care 16:517-521, 2004